[Drug therapy of Menière's disease].
D000208:Acute Disease; D001299:Audiometry; D003864:Depression, Chemical; D003911:Dextrans / Q000627:therapeutic use*; D004322:Drainage; D007758:Ear, Inner / Q000098:blood supply; D004487:Edema / Q000517:prevention & control; D006311:Hearing Disorders / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D008575:Meniere Disease / Q000188:drug therapy* / Q000628:therapy; D009243:NAD / Q000096:biosynthesis; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D010101:Oxygen Consumption / Q000187:drug effects; D011188:Potassium / Q000032:analysis; D012039:Regional Blood Flow / Q000187:drug effects; D012964:Sodium / Q000032:analysis; D013806:Theophylline / Q000008:administration & dosage / Q000627:therapeutic use*; D014867:Water / Q000032:analysis
D003911:Dextrans; D009539:Nicotinic Acids; D014867:Water; D009243:NAD; D012964:Sodium; D013806:Theophylline; D011188:Potassium
Zur medikamentösen Behandlung des Morbus Menière.